Aktuellt
SENASTE
Redeye is encouraged by Fluoguide communicating excellent safety and promising early signs of efficacy from the completed first part of its phase I/II high-grade glioma trial. Overall, 40 patients received FG001 treatment, and the company has determined optimal timing and dose for part 2 of the trial. Histology data confirmed FG001 lighting up aggressive brain cancer tissue. We judge that the presented results confirm the promising part 1 results that the company announced last year, but we would like to see more granular histology data in the future.
LÄS MER
